Medical Management of Parkinson's Disease after Initiation of Deep Brain Stimulation

Can J Neurol Sci. 2016 Sep;43(5):626-34. doi: 10.1017/cjn.2016.274.

Abstract

In this review, we have gathered all the available evidence to guide medication management after deep brain stimulation (DBS) in Parkinson's disease (PD). Surprisingly, we found that almost no study addressed drug-based management in the postoperative period. Dopaminergic medications are usually reduced, but whether the levodopa or dopamine agonist is to be reduced is left to the personal preference of the treating physician. We have summarized the pros and cons of both approaches. No study on the management of cognitive problems after DBS has been done, and only a few studies have explored the pharmacological management of such DBS-resistant symptoms as voice (amantadine), balance (donepezil) or gait disorders (amantadine, methylphenidate). As for the psychiatric problems so frequently reported in PD patients, researchers have directed their attention to the complex interplay between stimulation and reduction of dopaminergic drugs only recently. In conclusion, studies addressing medical management following DBS are still needed and will certainly contribute to the ultimate success of DBS procedures.

Keywords: Deep brain stimulation; Globus pallidus internus; Medication; Parkinson’s disease; Subthalamic nucleus.

Publication types

  • Review

MeSH terms

  • Antiparkinson Agents / therapeutic use*
  • Cognition Disorders / drug therapy
  • Cognition Disorders / etiology
  • Deep Brain Stimulation / methods*
  • Disease Management*
  • Humans
  • Parkinson Disease / complications
  • Parkinson Disease / therapy*

Substances

  • Antiparkinson Agents